Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer

Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer

Abstract Regorafenib has shown significant survival benefit as a salvage therapy for colorectal cancer; however, its starting dose has been controversial in recent studies. Therefore, we conducted a prospective study on the efficacy and safety of the dose reduction of regorafenib to 120 mg. Patients...

Full description

Bibliographic Details
Main Authors: Takeshi Kato, Toshihiro Kudo, Yoshinori Kagawa, Kohei Murata, Hirofumi Ota, Shingo Noura, Junichi Hasegawa, Hiroshi Tamagawa, Katsuya Ohta, Masakazu Ikenaga, Susumu Miyazaki, Takamichi Komori, Mamoru Uemura, Junichi Nishimura, Taishi Hata, Chu Matsuda, Taroh Satoh, Tsunekazu Mizushima, Yuko Ohno, Hirofumi Yamamoto, Yuichiro Doki, Hidetoshi Eguchi
Format: Article
Language:English
Published: Nature Portfolio 2023-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-24057-0

Internet

https://doi.org/10.1038/s41598-022-24057-0

Similar Items